The 4-aminoquinoline drugs, such as chloroquine (CQ), amodiaquine or piperaquine, are still commonly used for malaria treatment, either alone (CQ) or in combination with artemisinin derivatives. We previously described the excellent in vitro activity of a novel pyrrolizidinylmethyl derivative of 4-amino-7-chloroquinoline, named MG3, against P. falciparum drug-resistant parasites. Here, we report the optimized and safer synthesis of MG3, now suitable for a scale-up, and its additional in vitro and in vivo characterization. MG3 is active against a panel of P. vivax and P. falciparum field isolates, either alone or in combination with artemisinin derivatives. In vivo MG3 is orally active in the P. berghei, P. chabaudi, and P. yoelii models of rodent malaria with efficacy comparable, or better, than that of CQ and of other quinolines under development. The in vivo and in vitro ADME-Tox studies indicate that MG3 possesses a very good pre-clinical developability profile associated with an excellent oral bioavailability, and low toxicity in non-formal preclinical studies on rats, dogs, and non-human primates (NHP). In conclusion, the pharmacological profile of MG3 is in line with those obtained with CQ or the other quinolines in use and seems to possess all the requirements for a developmental candidate.

Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities / N. Basilico, S. Parapini, S. D’Alessandro, P. Misiano, S. Romeo, G. Dondio, V. Yardley, L. Vivas, S. Nasser, L. Rénia, B.M. Russell, R. Suwanarusk, F. Nosten, A. Sparatore, D. Taramelli. - In: BIOMOLECULES. - ISSN 2218-273X. - 13:5(2023 May 14), pp. 836.1-836.23. [10.3390/biom13050836]

Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities

N. Basilico
Co-primo
;
S. Parapini
Co-primo
;
S. D’Alessandro
Secondo
;
P. Misiano;S. Romeo;A. Sparatore
Penultimo
;
D. Taramelli
Ultimo
2023

Abstract

The 4-aminoquinoline drugs, such as chloroquine (CQ), amodiaquine or piperaquine, are still commonly used for malaria treatment, either alone (CQ) or in combination with artemisinin derivatives. We previously described the excellent in vitro activity of a novel pyrrolizidinylmethyl derivative of 4-amino-7-chloroquinoline, named MG3, against P. falciparum drug-resistant parasites. Here, we report the optimized and safer synthesis of MG3, now suitable for a scale-up, and its additional in vitro and in vivo characterization. MG3 is active against a panel of P. vivax and P. falciparum field isolates, either alone or in combination with artemisinin derivatives. In vivo MG3 is orally active in the P. berghei, P. chabaudi, and P. yoelii models of rodent malaria with efficacy comparable, or better, than that of CQ and of other quinolines under development. The in vivo and in vitro ADME-Tox studies indicate that MG3 possesses a very good pre-clinical developability profile associated with an excellent oral bioavailability, and low toxicity in non-formal preclinical studies on rats, dogs, and non-human primates (NHP). In conclusion, the pharmacological profile of MG3 is in line with those obtained with CQ or the other quinolines in use and seems to possess all the requirements for a developmental candidate.
kidney transplant; immunosuppression; virus-related malignancy; trend; Italy; cohort study;
Settore MED/04 - Patologia Generale
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
   Towards multi-stage drugs to fight poverty related and neglected parasitic diseases: synthetic and natural compounds directed against Leishmania, Plasmodium and Schistosoma life stages and assessment of their mechanisms of action.
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   20154JRJPP_004

   La risposta infiammatoria della cute ad agenti infettivi e danno tissutale: analisi trascrittomica, post-trascrittomica e studi funzionali a livello della singola cellula. Acronimo: SKINFLAM
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2010C2LKKJ_006

   Gametocyte Assay for MAlaria (GAM) for Novel Anti-Transmission Drugs
   BILL & MELINDA GATES FOUNDATION
14-mag-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
biomolecules-13-00836-v2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.03 MB
Formato Adobe PDF
3.03 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/969918
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact